Skip to main content
OpenTrials
Completed

NCT Number: NCT01656057

The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion

The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but also modulates the energy expenditure in (brown) adipose tissue and muscle tissue. This action is due to stimulation of the receptor TGR5 by bile acids. Recently scientists have discovered that this receptor in rodents is also expressed on the surface of intestinal L-cells (which normally secrets Glucagon-Like Peptide-1 (GLP-1) in response to nutrient stimulation). The stimulation of this receptor has shown a GLP-1 secretion from the intestinal cells which is interesting since GLP-1 has a central role in maintaining normal glucose tolerance and thus blood sugar. Given the above, bile acids has an important impact on intestinal GLP-1 secretion. Whether these scientific findings can be proven in human beings is uncertain.

The primary hypothesis is that stimulating gall bladder emptying via Cholecystokinin (CCK) in healthy subjects will result in a significant GLP-1 response. We also hypothesize that adding orally Metformin or a sequestrant ("a bile acid binder") will further enhance this GLP-1 response.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division

Copenhagen, Hellerup, 2900, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HbA1c < 6,0%
  • Not anaemic
  • Written informed consent

Exclusion criteria

  • Liver disease
  • Nephropathy
  • fasting plasma glucose > 5,6mM
  • Diabetes running in the family (parents or grandparents)
  • Any medical treatment
  • A former medical history of liver- or bile disease
  • any surgical procedure conducted in the abdomen
  • Body mass index < 18,5 kg/m2 or > 25 kg/m2

Treatment and study plan

Acetaminophen

Drug

Acetaminophen dissolved in 50 ml of water

Other names: Paracetamol

metformin

Drug

Metformin + acetaminophen dissolved in 50 ml of water

Colesevelam

Drug

Colesevelam + acetaminophen dissolved in 50 ml of water

Cholecystokinin-8

Other

iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes

Other names: CCK-8

Saline

Other

iv. saline infusion 40 ml/hour for the first 60 minutes

Primary outcomes

  1. GLP-1 response as incremental area under curve (iAUC)

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

Secondary outcomes

  1. Insulin

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

Other outcomes

  1. c-peptide

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  2. glucagon

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  3. Glucagon-Like Peptide-2

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  4. Peptide YY

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  5. Oxyntomodulin

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  6. Glucose-Dependent Insulinotropic Peptide

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  7. Bile acids

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  8. Gastrin

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  9. CCK

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

  10. Gall bladder emptying assessed ultrasonically

    Time frame: -30, -15, 20, 40, 60, 90, 120, 150, 180

  11. Resting energy expenditure

    Time frame: -10, 50, 210

  12. Estimation of satiety via visual analogue scale

    Time frame: 0, 30, 60, 90, 120, 150, 180, 240

Sponsors and collaborators

Lead sponsor

Filip Krag Knop

Other

Collaborators

  • University of Copenhagen

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Aug 2, 2012
Registry last updated
Jul 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.